On 29 July 2004, orphan designation (EU/3/04/213) was granted by the European Commission to SmithKline Beecham plc, United Kingdom, for mepolizumab for the treatment of hypereosinophilic syndrome.
The sponsorship was transferred to Glaxo Group Limited, United Kingdom, in September 2008.
The sponsorship was transferred to GlaxoSmithKline Trading Services Limited, Ireland, in May 2018.
The sponsor’s address was updated in April 2020. In April 2020, GlaxoSmithKline Trading Services Limited changed name to GlaxoSmithKline (Ireland) Limited.
|Disease / condition||
Treatment of hypereosinophilic syndrome
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.